Harrow (NASDAQ:HROW) Now Covered by Analysts at BTIG Research

Equities researchers at BTIG Research initiated coverage on shares of Harrow (NASDAQ:HROW) in a research note issued on Thursday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $62.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 96.14% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright lifted their target price on shares of Harrow from $57.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, May 12th. B. Riley cut their target price on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Finally, William Blair assumed coverage on Harrow in a research note on Tuesday. They set an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $61.40.

Harrow Stock Performance

NASDAQ:HROW opened at $31.61 on Thursday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -33.63 and a beta of 0.40. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a 1-year low of $16.87 and a 1-year high of $59.23. The business has a 50 day moving average of $25.84 and a 200 day moving average of $29.84.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analysts’ expectations of $57.00 million. Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. On average, sell-side analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Harrow

Several hedge funds and other institutional investors have recently modified their holdings of HROW. GF Fund Management CO. LTD. bought a new position in Harrow in the 4th quarter worth $25,000. Quarry LP purchased a new stake in Harrow during the first quarter valued at $32,000. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company’s stock valued at $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in Harrow during the fourth quarter worth $78,000. Finally, AlphaQuest LLC lifted its stake in Harrow by 452.8% in the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.